London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To be honest I am not really sure about the 30%. being pedantic you cant divide 100 by 3 and get 30%. Does that mean safe in all 3 (or at least manageable side effects) with 1 showing signs of efficacy would equal success? That is kind of how I am reading it. Also the definition of success is important because we don't know the end points of the study -n of 3 is normally the minimum from a statistical point of view that you would select for very early stage feasibility it may not be the number of patients required to meet the clinical protocol end point. So my take is that the n-3 could provide initial proof of concept in humans which if successful (1 out of 3 showing efficacy) may be enough to access the non-dilutive funds mentioned to complete the phase1/2a study in a total of 18 AML patients. At that point the efficacy in patient population would be further understood and if Hemo CAR-T does show signs of efficacy then it would significantly de-risk the program and open doors to the big numbers that were mentioned in the article that pharma companies will pay for CAR-T products in the oncology space.
Goldwater - whats being made up and by who?
I'd personally wait for Haywain's view on how the 30% might work.
SB,
So basically, if you are looking at this purely from an odds/percentage point of view, if they use 3 patients and one of them is successful, there is a 90% chance of that happening. I'll take those odds any day. If that happens, imagine what the company will be worth then. A hell of a lot higher than a poxy 1.6p
Thanks SB, very helpful.
Goldwater...the market sounding deck had a number targetted for the raise and mentioned 1 patient. The covering email that it was attached to though suggested ~3 (and I asked them why the difference between doc and cover email, didn't get an answer). Then the raise came in at a larger amount and it suggested to me that 3 was likely tied to them raising more than the initial target which they did. That's the info I'm working on. You can choose whether or not you want to believe me, I don't care...if you want to play conspiracy games and if you decide I'm making the above up....am I ramping or deramping? Good luck with figuring that out.
The only ones who may be close to getting the logistical plans confirmed is Haywain on here or HEMO themselves. Everyone else is just speculating in trying to ramp or deramp the price.
This is dead as a dodo until we get some update on all the things vlad promised us as always !!!
@Investor6
The way I read is as follows.
At this stage 30% is a success.
So pretty much 1 out of 3.
So if Hemogenyx get the desired results with just 1 out of the planned 3, then it is deemed a success.
If (hopefully WHEN) we get those positive results, I would expect that Hemogenyx can access those non dilutive funds they are talking about.
Or that a big pharma is interested in a JV that is also beneficial to us.
That's my take on the interview.
Would think some news can't be far off :)
No body knows when the clinical trial is or How many people. Stop making thing up.
No
So the fundraise created enough cash to fund only 3 patients, but they need a funds to test 15 more patients before it can become a success?
Am I reading that correctly?
That interview is a guide only. But working back from December the first patient could embark on treatment at the beginning of September (and hopefully much sooner than that)
Not quite made up Gold...
https://www.proactiveinvestors.co.uk/companies/news/1044876/hemogenyx-pharmaceuticals-important-raise-and-car-t-potential-makes-it-one-to-watch-1044876.html?viewSource=TwitterUK
''Hemogenyx will use the newly raised funds to take HEMO-CAR-T into the clinic to treat AML later this year.
The open-label study will test for any potential side effects from treating people with blood-borne diseases and assess how the therapy interacts with the body.
A secondary goal or 'endpoint' will be whether any of the critically ill AML patients chosen for the trial respond to the CAR-T infusion.
Under the strict guidelines laid down by the US Food & Drug Administration, patients will be dosed individually one month apart, recognising people are being administered with a potentially toxic cells.
Hemogenyx hopes to have the results from “two, or even three patients” in time for the American Society of Hematology conference in early December.
Success at this stage would be a 30% response rate, says Dr Vladislav Sandler, chief executive and co-founder of Hemogenyx.
Investigational work will be carried out by a team from the University of Pennsylvania, led by Professor Nolle Frey, who has headed a number of important CAR-T clinical trials.
The entre was provided by Professor Carl June, the ‘father’ of CAR-T, and his colleague, Dr Saar Gill, who was involved in the preclinical research on HEMO-CAR-T.
On the university’s involvement, Sandler said: “This isn’t a situation where we’ve paid [UPenn] to carry out the work. They don’t work like that. All along it been data driven.”
While no guarantee of success, it provides validation for the science behind the efforts of Hemogenyx.
So expensive is the process of creating individual CAR-T treatments, that cash raised in February may be enough to dose three patients.
Hemogenyx will look to further non-dilutive funding to assess a cohort of around 18 AML sufferers, which will take it to the phase II stage of the clinical evaluation.
This is key, as it is the point that big pharma has weighed into the sector with the deals mentioned above''
Thanks Mr india.
I have read the RNS from March. I just could not understood where some people are saying about 3 person are receiving the treatment.
Just made up stories.
Just use Google....why not look at JV investments and pharma licencing deals why you are diving around
I have never been through the delist scenario so you're right, I have no idea and figured as it was a topic of conversation it'd be fair to ask for the cliff notes. I can do my own research, it'll just take me a little longer, thanks stu for giving something to dive into here
Afternoon all
To note -
Stock on loan / shorts
4.75 million
4.2 million opened 2 weeks ago @ 1.6 - costing money to keep open & making nowt - unlucky
a 500k short was opened yesterday
Perhaps attached to some of the negativity on here , who knows who cares ,
Current stock price 1.61 - + blue -
Vol - 6.3 million - thin
Let’s all invested hope a decent RNS drops & gets this clinical party started .
The recent article posted about Hemo was certainly loaded with potential for investors .
Let’s see what next few weeks bring
Goldwater ... no one on this site knows anything on timelines or whats really happening in hemo. Haywain is our resident super scientist. I would suggest you either look through the old RNSs and videos or contact hemo directly since this place is just full of rampers and derampers with their own agendas ... especially Stu who has suddenly reappeared. Maybe he knows as he seems to know when placing and other things are coming !!!
Still waiting for the RNS about the clinical trials. Anyone got any ideas when it might be.
Wasn't much of an apology Stu - no matter I didnt want an apology because I really am uninterested in what you have to say was just curious whether it would be provided - Fair do's, you have marginally gone up in my estimation. If you are implying that I have some sort of relationship with Hemo other than an investor you are wrong . I do however have 22 years of experience working on biologic products and the regulators (FDA included) mostly in rare oncology indications so call it what you like - educated guess
HT,
Yes that’s one possible explanation, there are others!!
AIMO
Ps Shicky’s still waiting.
It's because Haywain is a scientist, and you Stu, are a low life.
Haywire,
I’m happy you reminded me.
Yes , at present my prediction on the FDA’s concerns( not mine !) on the issue raised, has not resulted in any significant impact to those therapies and as such, presently my opinion has proven incorrect.
Always happy to stand corrected .
How is it , ahead of time your repeated posting of maybe 3 patients being dosed , ( very specific) and now the company confirming the same are so precise?
Congratulations on being spot on !!
AIMO
Stu, Er no, I certainly didn't know there was going to be a placing, and I didn't have any inside knowledge either. However, I strongly SUSPECTED there might be one, but only about 4/5 days before it actually came. I also started to offload quite a few shares because of that strong hunch. I have since bought back quite a few too, but not as many as I once initially held.